


RECORDATION FORM COVER SHEET PATENTS ONLY

Commissioner for Patents:

Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies):</p> <p>Hambrecht & Quist Guaranty Finance, LLC</p> <p>Additional name(s) of conveying party(ies) attached?</p> <p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and address of receiving party(ies):</p> <p>Name: CV Therapeutics, Inc.</p> <p>Internal Address:</p> <p>Street Address: 3172 Porter Drive</p> <p>City: Palo Alto State: CA Zip: 94304</p> <p>Additional name(s) & address(es) attached?</p> <p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>3. Nature of conveyance:</p> <p><input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input checked="" type="checkbox"/> Other: <u>Termination of Security Agreement</u></p> <p>Execution Date(s): March 23, 2005</p>	<p>Additional name(s) & address(es) attached?</p> <p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>4. Application number(s) or patent number(s):</p> <p>If this document is being filed together with a new application, the execution date of the application is:</p> <p>A. Patent Application No.(s) B. Patent No.(s)</p> <p style="text-align: center;">Please see attached sheet</p> <p style="text-align: right;">Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>J. Elin Hartrum CV Therapeutics, Inc. 3172 Porter Drive Palo Alto, CA 94304</p>	<p>6. Total number of applications & patents involved: 24</p> <p>7. Total fee (37 CFR 3.41) \$960.00</p> <p><input checked="" type="checkbox"/> Authorized to be charged to Deposit Account</p> <p>8. Deposit Account Number: 50-1789</p>
<p>9. Statement and signature</p> <p><i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i></p> <p>J. Elin Hartrum, Reg. No. 43,663  <u>3/24/2005</u></p> <p>Name of Person Signing Signature Date</p> <p style="text-align: center;">Total number of pages including cover sheet, attachments, and document: 5</p>	

Mail documents to be recorded with required cover sheet information to:

**Mail Stop Assignment Recordation Services
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

PATENT

REEL: 015953 FRAME: 0657

700165063

CH \$960.00 501789 4567264

Hambrecht & Quist Transition Capital, LLC

By: JPMorgan Chase & Co.

Its: Successor in Interest to Hambrecht & Quist Transition Capital, LLC

1**Patent #:** 4567264 **Issue Dt:** 01/28/1986**Application #:** 06495904 **Filing Dt:** 05/18/1983**Title:** CARDIOSELECTIVE ARYLOXY- AND ARYLTHIO-HYDROXYPROPYLENE-PIPERAZINYL ACETANILIDES WHICH AFFECT CALCIUM ENTRY**2****Patent #:** 5017565 **Issue Dt:** 05/21/1991**Application #:** 07340868 **Filing Dt:** 04/20/1989**Title:** USE OF SULFATED POLYSACCHARIDES TO INHIBIT PANCREATIC CHOLESTEROL ESTERASE**3****Patent #:** 5063210 **Issue Dt:** 11/05/1991**Application #:** 07429398 **Filing Dt:** 10/31/1989**Title:** USE OF SULFATED POLYSACCHARIDES TO DECREASE CHOLESTEROL AND FATTY ACID ABSORPTION**4****Patent #:** 5173408 **Issue Dt:** 12/22/1992**Application #:** 07434899 **Filing Dt:** 11/13/1989**Title:** MAMMALIAN PANCREATIC CHOLESTEROL ESTERASE**5****Patent #:** 5352601 **Issue Dt:** 10/04/1994**Application #:** 07936103 **Filing Dt:** 08/26/1992**Title:** METHOD FOR RECOVERING PURIFIED 52,000 DALTON FRACTION OF HUMAN PANCREATIC CHOLESTEROL ESTERASE USING DEAE-CELLULOSE, HYDROXYAPATITE AND HEPA RIN-SEPHAROSE**6****Patent #:** 5432058 **Issue Dt:** 07/11/1995**Application #:** 07954864 **Filing Dt:** 09/30/1992**Title:** METHOD FOR MEASURING HUMAN CHOLESTEROL ABSORPTION USING METABOLICALLY STABLE ISOTOPES**7****Patent #:** 5506229 **Issue Dt:** 04/09/1996**Application #:** 07955397 **Filing Dt:** 10/01/1992**Title:** NOVEL METHODS OF TREATMENT USING RANOLAZINE AND RELATED PIPERAZINE DERIVATIVES**8****Patent #:** 5446046 **Issue Dt:** 08/29/1995**Application #:** 08144459 **Filing Dt:** 10/28/1993**Title:** NOVEL A1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS AS DIURETICS

Hambrecht & Quist Transition Capital, LLC

- 9**
Patent #: 5484777 **Issue Dt:** 01/16/1996
Application #: 08167725 **Filing Dt:** 12/15/1993
Title: PANCREATIC CHOLESTEROL ESTERASE INHIBITOR
- 10**
Patent #: 5472707 **Issue Dt:** 12/05/1995
Application #: 08239621 **Filing Dt:** 05/09/1994
Title: HIGH DOSE RANOLAZINE FORMULATIONS
- 11**
Patent #: 5616570 **Issue Dt:** 04/01/1997
Application #: 08283723 **Filing Dt:** 08/01/1994
Title: USE OF NON-ABSORBABLE SYNTHETIC SULFATED POLYSACCHARIDES TO DECREASE CHOLESTEROL ABSORPTION
- 12**
Patent #: 5429937 **Issue Dt:** 07/04/1995
Application #: 08311862 **Filing Dt:** 09/26/1994
Title: METHOD FOR RECOVERING PURIFIED 100,000 MOLECULAR WEIGHT FRACTION OF HUMAN PANCREATIC CHOLESTEROL ESTERASE USING HEPARIN AGAROSE
- 13**
Patent #: 5521303 **Issue Dt:** 05/28/1996
Application #: 08322782 **Filing Dt:** 10/13/1994
Title: METHOD OF MANUFACTURING NON-ABSORBABLE SYNTHETIC SULFATED POLYSACCHARIDES
- 14**
Patent #: 5631260 **Issue Dt:** 05/20/1997
Application #: 08330640 **Filing Dt:** 10/28/1994
Title: XANTHINE EPOXIDES AS A1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS
- 15**
Patent #: 5492822 **Issue Dt:** 02/20/1996
Application #: 08386433 **Filing Dt:** 02/10/1995
Title: METHOD FOR RECOVERING PURIFIED 100,000 DALTON MOLECULAR WEIGHT FRACTION OF HUMAN PANCREATIC CHOLESTEROL ESTERASE
- 16**
Patent #: 5792832 **Issue Dt:** 08/11/1998
Application #: 08461881 **Filing Dt:** 06/05/1995
Title: PEPTIDES FROM MAMMALIAN PANCREATIC CHOLESTEROL ESTERASE
- 17**
Patent #: 5705451 **Issue Dt:** 01/06/1998
Application #: 08462889 **Filing Dt:** 06/05/1995
Title: THERMAL TRANSFER IMAGE-RECEIVING SHEET
- 18**
Patent #: 5840875 **Issue Dt:** 11/24/1998
Application #: 08467007 **Filing Dt:** 06/06/1995
Title: KIDNEY NA/PO4 COTRANSPORTER ANTISENSE OLIGONUCLEOTIDE

Hambrecht & Quist Transition Capital, LLC

19
Patent #: 5668139 **Issue Dt:** 09/16/1997
Application #: 08470113 **Filing Dt:** 06/06/1995
Title: NOVEL A1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS

20
Patent #: 5663450 **Issue Dt:** 09/02/1997
Application #: 08470974 **Filing Dt:** 06/06/1995
Title: MACROPHAGE LIPID CHEMOATTRACTANT

21
Patent #: 5679375 **Issue Dt:** 10/21/1997
Application #: 08481751 **Filing Dt:** 06/07/1995
Title: METHOD OF TREATING ULCERS WITH SULFATED POLYSACCHARIDES

22
Patent #: 5906988 **Issue Dt:** 05/25/1999
Application #: 08628836 **Filing Dt:** 04/05/1996
Title: NOVEL METHODS OF TREATMENT USING RANOLAZINE AND RELATED PIPERAZINE DERIVATIVES

23
Patent #: 5866702 **Issue Dt:** 02/02/1999
Application #: 08692012 **Filing Dt:** 08/02/1996
Title: PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2

24
Patent #: 5789416 **Issue Dt:** 08/04/1998
Application #: 08702234 **Filing Dt:** 08/27/1996
Title: N6 MOMOHETEROCYCLIC SUBSTITUTED ADENOSINE DERIVATIVES



March 23, 2005

Ms. Lorraine Nield
Guaranty Finance Management, LLC
180 Pacific Avenue
San Francisco, CA 94111

Re: Master Lease Agreement between CV Therapeutics, Inc. and Hambrecht & Quist Guaranty Finance, LLC, dated 9/27/96, as amended 3/7/97 and 5/19/97.

Dear Lorraine:

Given that all obligations pursuant to the above-indicated Master Lease Agreement ("Lease") were fulfilled as of 5/1/99, please acknowledge, by signing below, that this Lease and all Related Documents, as defined in the Lease, including, but not limited, to the Security Agreement between CV Therapeutics, Inc. and Hambrecht & Quist Guaranty Finance, LLC, dated 9/27/96, as amended 3/7/97 and 5/19/97, have been terminated.

Best regards,

Christopher Y. Chai
Vice President, Treasury & Investor Relations
(650) 812-9560

Acknowledged as Paid in Full

Hambrecht & Quist Guaranty Finance, LLC

By: Hambrecht & Quist Guaranty Finance, LLC

By: Guaranty Finance Management, LLC
Its Manager and Authorized Representative

By: Lorraine Nield 3/23/2005
Title: Manager, CFO